Breast Cancer
CE/CME accredited
touchIN CONVERSATION
A relaxed discussion between two faculty focussed on real world clinical issues. Useful tips below will show how to navigate the activity. Join the conversation.
Close
sharing perspectives specific dees through the lens of a paediatric and an adult neurologist
Videos
Learning Objectives & Overview
Claim Credit
Toolkit
Notes
This activity is CE/CME accredited
To obtain the credit(s) from this activity, please complete this post-activity test.
Claim Credit
You may also be interested in...
touchPANEL DISCUSSION
New and emerging agents in HER2-negative metastatic breast cancer: Implications for current and future practice
This activity is CE/CME accredited
LAUNCH ACTIVITY
CONFERENCE HUB
Sara Hurvitz, SABCS 2022: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2+ metastatic breast cancer: DESTINY-Breast03
GO TO HUB
CONFERENCE HUB
Nancy Lin, SABCS 2021: Updated Results of the HER2CLIMB Study
GO TO HUB
touchEXPERT OPINIONS
HR+/HER2- advanced breast cancer: How do the latest data on CDK4/6 inhibitors inform clinical decision-making?
LAUNCH ACTIVITY
JOURNALS
Neoadjuvant Chemotherapeutic and Targeted Therapies for Early-stage, High-risk Breast Cancer
GO TO ARTICLE
JOURNALS
Novel Cytotoxic Agents in Chemotherapy-resistant Metastatic Breast Cancer – The Epothilones
GO TO ARTICLE
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGY
Claim Credit
touchIN CONVERSATION
sharing perspectives specific dees through the lens of a paediatric and an adult neurologist
You may also be interested in...
CONFERENCE HUB
Angela DeMichele, ASCO 2023: The PALLAS trial, palbociclib with adjuvant endocrine therapy in patients with stage II-III breast cancer
GO TO HUB
touchPANEL DISCUSSION
New horizons in high-risk HR+ HER2- EBC: Risk stratification for early identification and novel treatment strategies
This activity is CE/CME accredited
LAUNCH ACTIVITY
touchCONGRESS
Utilizing the latest data from SABCS 2020 to optimize the management of patients with HR+/HER2- breast cancer
This activity is CE/CME accredited
LAUNCH ACTIVITY
CONFERENCE HUB
Claudio Zamagni, ESMO 2018 – The CompLEEment-1 Trial in Advanced Breast Cancer
GO TO HUB
JOURNALS
Magnetic Resonance Imaging Gaining Importance in Breast Cancer High-risk Screening and Disease Management
GO TO ARTICLE
JOURNALS
The Importance of Distant Metastasis and Its Impact on Survival Rates on Early-stage Hormone Receptor-positive Breast Cancer
GO TO ARTICLE
Copied to clipboard!
accredited arrow-down-editable arrow-down arrow_left arrow-right-blue arrow-right-dark-blue arrow-right-green arrow-right-grey arrow-right-orange arrow-right-white arrow-right-blue arrow-up-orange avatar calendar chevron-down Clicky Media Logo consultant-pathologist-nurse consultant-pathologist cross cross download email exclaimation feedback filter graph-arrow interviews link mdt_icon more_dots nurse-consultant padlock patient-advocate-pathologist patient-consultant patient person pharmacist-nurse play_button play-colour-tmc play-colour Asset 1 podcast printer scenery search share single-doctor social_facebook social_googleplus social_instagram social_linkedin_alt social_linkedin_alt social_pinterest social_youtube shape-star (1) tick-blue tick-orange tick-red tick-white tick time transcript up-arrow webinar
Department Location NEW TMM Corporate Services Icons-07 NEW TMM Corporate Services Icons-08 NEW TMM Corporate Services Icons-09 NEW TMM Corporate Services Icons-10 NEW TMM Corporate Services Icons-11 NEW TMM Corporate Services Icons-12 Salary £ TMM-Corp-Site-Icons-01 TMM-Corp-Site-Icons-02 TMM-Corp-Site-Icons-03 TMM-Corp-Site-Icons-04 TMM-Corp-Site-Icons-05 TMM-Corp-Site-Icons-06 TMM-Corp-Site-Icons-07 TMM-Corp-Site-Icons-08 TMM-Corp-Site-Icons-09 TMM-Corp-Site-Icons-10 TMM-Corp-Site-Icons-11 TMM-Corp-Site-Icons-12 TMM-Corp-Site-Icons-13 TMM-Corp-Site-Icons-14 TMM-Corp-Site-Icons-15 TMM-Corp-Site-Icons-16 TMM-Corp-Site-Icons-17 TMM-Corp-Site-Icons-18 TMM-Corp-Site-Icons-19 TMM-Corp-Site-Icons-20 TMM-Corp-Site-Icons-21 TMM-Corp-Site-Icons-22 TMM-Corp-Site-Icons-23 TMM-Corp-Site-Icons-24 TMM-Corp-Site-Icons-25 TMM-Corp-Site-Icons-26 TMM-Corp-Site-Icons-27 TMM-Corp-Site-Icons-28 TMM-Corp-Site-Icons-29 TMM-Corp-Site-Icons-30 TMM-Corp-Site-Icons-31 TMM-Corp-Site-Icons-32 TMM-Corp-Site-Icons-33 TMM-Corp-Site-Icons-34 TMM-Corp-Site-Icons-35 TMM-Corp-Site-Icons-36 TMM-Corp-Site-Icons-37 TMM-Corp-Site-Icons-38 TMM-Corp-Site-Icons-39 TMM-Corp-Site-Icons-40 TMM-Corp-Site-Icons-41 TMM-Corp-Site-Icons-42 TMM-Corp-Site-Icons-43 TMM-Corp-Site-Icons-44 TMM-Corp-Site-Icons-45 TMM-Corp-Site-Icons-46 TMM-Corp-Site-Icons-47 TMM-Corp-Site-Icons-48 TMM-Corp-Site-Icons-49 TMM-Corp-Site-Icons-50 TMM-Corp-Site-Icons-51 TMM-Corp-Site-Icons-52 TMM-Corp-Site-Icons-53 TMM-Corp-Site-Icons-54 TMM-Corp-Site-Icons-55 TMM-Corp-Site-Icons-56 TMM-Corp-Site-Icons-57 TMM-Corp-Site-Icons-58 TMM-Corp-Site-Icons-59 TMM-Corp-Site-Icons-60 TMM-Corp-Site-Icons-61 TMM-Corp-Site-Icons-62 TMM-Corp-Site-Icons-63 TMM-Corp-Site-Icons-64 TMM-Corp-Site-Icons-65 TMM-Corp-Site-Icons-66 TMM-Corp-Site-Icons-67 TMM-Corp-Site-Icons-68 TMM-Corp-Site-Icons-69 TMM-Corp-Site-Icons-70 TMM-Corp-Site-Icons-71 TMM-Corp-Site-Icons-72